Monitor the annual meeting outcome for approval of the authorized share increase and equity plan amendment, which could signal future dilution. No immediate trading action warranted; the filing is routine.
Price Chart
Executive Summary
Protara Therapeutics filed definitive additional proxy materials for its 2026 Annual Meeting of Stockholders to be held on June 12, 2026. The board recommends voting FOR all director nominees, ratification of Ernst & Young as auditor, advisory approval of executive compensation, the equity incentive plan amendment, the increase in authorized shares from 100M to 200M, and officer exculpation, with a 1-year frequency for say-on-pay votes. This is a routine proxy solicitation with no contested matters or material financial disclosures.
Key Facts
- Annual meeting scheduled for June 12, 2026 at 12:00 PM ET
- Proposals include election of three Class III directors, ratification of Ernst & Young, advisory say-on-pay, frequency vote, amendment to 2024 Equity Incentive Plan, increase in authorized shares from 100M to 200M, and officer exculpation amendment
- Board recommends FOR all proposals and 1 YEAR for say-on-pay frequency
- No financial data or material business changes disclosed in the filing
Financial Impact
No material financial impact disclosed; routine governance proposals only.
Risk Factors
- Potential dilution if authorized share increase and equity plan amendments are approved and utilized
- No operational or financial updates provided in this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-048556 |
| Document: 0001213900-26-048556-index-headers.html | 0001213900-26-048556 |
| Document: 0001213900-26-048556-index.html | 0001213900-26-048556 |
| Document: 0001213900-26-048556.txt | 0001213900-26-048556 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 11, 2026 7w ago | 8-K | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Aug 11, 2026 7w ago | Press Release | $3.91 $3.83 | ▼ −2.05% | ▼ −0.99% | $2.70 (−30.95%) |
Jun 29, 2026 13w ago | 8-K | $3.82 $4.04 | ▲ +5.76% | ▲ +6.79% | $2.70 (−29.32%) |
May 26, 2026 18w ago | EFFECT | $4.80 $4.06 | ▲ +15.52% | ▲ +13.57% | $2.70 (+43.75%) |
May 15, 2026 20w ago | Press Release | $5.10 $3.94 | ▼ −22.75% | ▼ −24.86% | $2.70 (−47.06%) |
May 13, 2026 20w ago | 8-K | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
May 13, 2026 20w ago | Press Release | $5.20 $3.65 | ▼ −29.81% | ▼ −29.19% | $2.70 (−48.08%) |
Apr 28, 2026 22w ago | DEFA14A | $5.17 $4.75 | ▼ −8.12% | ▼ −14.17% | $2.70 (−47.78%) |
Mar 10, 2026 29w ago | Press Release | $5.71 $5.22 | ▼ −8.58% | ▼ −8.43% | $2.70 (−52.71%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access